Skip to main content
Premium Trial:

Request an Annual Quote

Enzon, Micromet End Antibody Drug R&D Partnership

NEW YORK, Nov. 28 (GenomeWeb News) - Enzon Pharmaceuticals and Micromet will end their collaboration to identify and develop antibody-based therapeutics for inflammatory and autoimmune diseases, the companies said today.


The decision was made after Enzon decided to redirect its efforts onto new business objectives, including a greater focus on cancer, the companies said. Enzon and Micromet had been collaborating since April 2002.


The companies said that the termination of their collaboration does not affect their other agreements, including a cross-license agreement between the parties and a marketing agreement under which Micromet is the exclusive marketer of the companies' combined intellectual property estate in the field of single-chain antibody technology.

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.